Form 4: Immix Biopharma CFO Gabriel Morris Granted 340,000 Stock Options

Immix Biopharma, Inc. (IMMX) announced that its CFO and Director, Gabriel S. Morris, was granted 340,000 stock options with an exercise price of $2.24, vesting over 48 months.

Summary

• Gabriel S. Morris, who serves as the Chief Financial Officer and a Director of Immix Biopharma, Inc. (IMMX), was granted 340,000 stock options.
• The stock options have an exercise price of $2.24 per share.
• These options are scheduled to vest in 48 equal monthly installments, commencing from the grant date of June 20, 2025.
• The expiration date for the granted stock options is June 20, 2035.
• Following this transaction, Mr. Morris directly beneficially owns 288,059 shares of Common Stock and 340,000 stock options.
• He also indirectly beneficially owns 270,844 shares of Common Stock through Alwaysraise LLC and 24,141 shares through Alwaysraise Ventures I, LP, though he disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive event as it aligns management's interests with shareholders and incentivizes long-term performance and retention. While it introduces potential future dilution, this is a standard and expected component of executive compensation.

Positives

• The grant of stock options to CFO Gabriel S. Morris aligns his financial interests with those of the shareholders, incentivizing long-term company performance and value creation.
• The 48-month vesting schedule promotes the retention of key management personnel, ensuring continuity and stability in leadership.

Negatives

• The future exercise of these stock options could lead to dilution for existing shareholders, although this is a common and expected aspect of equity-based compensation plans.

Risks

• Potential future dilution of existing shareholder equity if the 340,000 stock options are exercised.
• The value realized from these options by the reporting person is contingent upon the future stock price performance of Immix Biopharma, Inc.

Future Outlook

NA

Industry Context

This Form 4 filing details a routine individual insider transaction related to executive compensation. It does not provide broader industry context or trends, as its scope is limited to the specific equity grant to a company officer.

Related Party Transactions

• Gabriel Morris's indirect beneficial ownership through Alwaysraise LLC and Alwaysraise Ventures I, LP, where he disclaims beneficial ownership except for his pecuniary interest, indicates existing related party structures for holding company shares.

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise of options, but also benefit from increased alignment of management's interests with long-term company performance.
• Management: Gabriel Morris receives a significant equity incentive, directly linking his compensation to the company's stock performance and promoting his retention.
• Employees: No direct impact on general employees, but reinforces the company's compensation structure for executives.

Next Steps

• The stock options will vest in 48 equal monthly installments following the grant date of June 20, 2025, contingent upon Gabriel Morris's continued service with Immix Biopharma, Inc.

Key Dates

Recommendation

Keywords

Immix Biopharma, IMMX, Gabriel Morris, Stock Options, Equity Compensation, SEC Form 4, Insider Transaction, CFO, Director, Beneficial Ownership